Anlotinib plus chemotherapy for T790M‐negative EGFR ‐mutant non‐sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial

BACKGROUND: This multicenter phase 1b/2 trial aimed to explore the maximum tolerated dose (MTD), activity, and safety of anlotinib plus chemotherapy in patients with T790M‐negative epidermal growth factor receptor (EGFR)‐mutant advanced nonsquamous non‐small cell lung cancer (NSCLC) after resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Juan, Tian, Yuke, Zheng, Min, Ge, Jun, Zhang, Jiliang, Kong, Dejun, Chen, Mei, Yu, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750808/
https://www.ncbi.nlm.nih.gov/pubmed/36346139
http://dx.doi.org/10.1111/1759-7714.14713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750808/
https://www.ncbi.nlm.nih.gov/pubmed/36346139
http://dx.doi.org/10.1111/1759-7714.14713

Ejemplares similares